Archives of Medical Research
Volume 41, Issue 3 , Pages 190-194 , April 2010

Decreased 1-25 Dihydroxyvitamin D3 Concentration in Peripheral Blood Serum of Patients with Thyroid Cancer

  • Tomasz Stepien

      Affiliations

    • Departament of Endocrine and General Surgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Roman Krupinski

      Affiliations

    • Departament of Endocrine and General Surgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Jan Sopinski

      Affiliations

    • Departament of Endocrine and General Surgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Krzysztof Kuzdak

      Affiliations

    • Departament of Endocrine and General Surgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    • ,
  • Jan Komorowski

      Affiliations

    • Department of Clinical Endocrinology, Medical University of Lodz, Lodz, Poland
    • ,
  • Hanna Lawnicka

      Affiliations

    • Department of Immunoendocrinology, Medical University of Lodz, Lodz, Poland
    • ,
  • Henryk Stepien

      Affiliations

    • Department of Immunoendocrinology, Medical University of Lodz, Lodz, Poland
    • Corresponding Author InformationAddress reprint requests to: Prof. Dr. Henryk Stepien M.D., PhD., Department of Immunoendocrinology, Medical University of Lodz, ul. Dr. Sterling 3, 91-425, Lodz, Poland; Phone: +48426324854; FAX: +48426324854

Received 21 October 2009 ,Accepted 30 March 2010.

References 

  1. Enewold T, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–791
  2. Steliarova-Foucher E, Stiller CA, Pukkala E, et al. Thyroid cancer incidence and survival among European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2150–2169
  3. Said S, Schlumberger M, Suarez HG. Oncogenes and anti-oncogenes in human epithelial thyroid tumors. J Endocrinol Invest. 1994;17:371–379
  4. Melillo RM, Cirafici AM, De Falco V, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Am J Pathol. 2004;165:511–521
  5. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol. 2006;96:662–669
  6. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19:468–483
  7. Holick MF. Sunlight and vitamin D: both good for cardiovascular health. J Gen Intern Med. 2002;17:733–735
  8. Hart GR, Furniss JL, D. Laurie D, et al. Measurement of vitamin D status: background, clinical use, and methodologies. Clin Lab. 2006;52:335–343
  9. Fife RS, Sledge GW, Proctor C. Effects of vitamin D3 on proliferation of cancer cells in vitro. Cancer Lett. 2007;120:65–69
  10. Hershberger PA, Modzelewski RA, Shurin ZR, et al. 1,25-dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999;59:2644–2649
  11. Wu G, Fan RS, Li W, et al. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene. 1997;15:1555–1563
  12. Cross HS, Peterlik M, Reddy GS, et al. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol. 1997;62:21–28
  13. Khadzkou K, Buchwald P, Westin G, et al. 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid carcinoma. J Histochem Cytochem. 2006;54:355–361
  14. Segersten U, Holm PK, Björklund P, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res. 2005;7:980–986
  15. Feskanich D, Ma DJ, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2004;13:1502–1508
  16. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005;16:83–95
  17. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92:49–59
  18. Crew KD, Gammon MD, Steck SE, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila Pa). 2009;2:598–604
  19. Cross HS, Kallay E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol. 2009;5:493–507
  20. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, et al. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 2009;69:1439–1447
  21. Speers C, Brown CP. Breast cancer prevention using calcium and vitamin D: a bright future?. J Natl Cancer Inst. 2008;100:1562–1564
  22. Jensen SS, Madsen MW, Lukas EJ, et al. Inhibitory effects of 1alpha,25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery. Mol Endocrinol. 2001;15:1370–1380
  23. Zhuang SH, Burnstein KL. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998;139:1197–1207
  24. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004;229:277–284
  25. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7:684–700
  26. Byrne B, Welsh J. Identification of novel mediators of vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells. J Steroid Biochem Mol Biol. 2007;103:703–707
  27. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem. 2001;276:9101–9107
  28. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin. 2007;28:1373–1382
  29. Ondková S, Macejová D, Brtko J. Role of dihydroxyvitamin D3 and its nuclear receptor in novel directed therapies for cancer. Gen Physiol Biophys. 2006;25:339–353
  30. Alagbala AA, Johnson CS, Trump DL, et al. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and GH QW-1624F2-2) in squamous cell carcinoma cells. Oncology. 2006;70:483–492
  31. Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008;17:889–894
  32. Morishita M, Ohtsuru A, Kumagai A, et al. Vitamin D3 treatment for locally advanced thyroid cancer: a case report. Endocr J. 2005;52:613–616
  33. Ahn J, Peters D, Albanes D, et al. Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100:796–804
  34. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer–results of a large case-control study. Carcinogenesis. 2008;29:93–99
  35. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Rev Mol Cancer Ther. 2006;5:797–808
  36. Kliewer SA, Umesono K, Mangelsdorf DJ, et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature. 1992;355:446–449
  37. Malloy PJ, Feldman D. Vitamin D resistance. Am J Med. 1999;106:355–370
  38. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–894
  39. Lamberg-Allardt C, Valtonen E, Polojarvi M, et al. Characterization of a 1,25-dihydroxy-vitamin D3 receptor in FRTL-5 cells. Evidence for an inhibitory effect of 1,25-dihydroxy-vitamin D3 on thyrotropin-induced iodide uptake. Mol Cell Endocrinol. 1991;81:25–31
  40. Okano K, Usa T, Ohtsuru A, et al. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J. 1999;46:243–252
  41. Liu W, Asa SL, Fantus IG, et al. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol. 2002;160:511–519
  42. Verstuyf A, Segaert S, Verlinden L, et al. Recent developments in theuse of vitamin D analogues. Expert Opin Investig Drugs. 2000;9:443–455
  43. Dackiw AP, Ezzat S, Huang P, et al. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology. 2004;145:5840–5846

PII: S0188-4409(10)00076-7

doi: 10.1016/j.arcmed.2010.04.004

Archives of Medical Research
Volume 41, Issue 3 , Pages 190-194 , April 2010

Article Tools

* Image Usage & Resolution